Clinical Trial

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care and to a placebo.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-11-12; most recent amendment 2026-06-22.
Trial Details
NCT Number NCT07227909
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Usona Institute
Conditions Psilocybin, Neuropathy
Enrollment 83 participants
Start Date 2026-11-04
Primary Completion 2029-01-31 (estimated)
Study Completion 2031-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12